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Ethics in a Global 
Biopharmaceutical 
Environment 
Michael J. Malinowski∗ 
I.  Introduction 
Pharmaceuticals and biologics (biotech products) have integrated into 
biopharmaceuticals, sharpening the focus on genomics (gene function) and 
proteomics (protein function) in drug development.1  Moreover, the forefront of the 
“genomics revolution” has advanced: scientists now are grappling with the 
challenge of making medical sense out of the completed map of the human 
genome.2  The means to meet this challenge is bioinformatics — the combination 
 
∗ Ernest R. and Iris M. Eldred Endowed Professor of Law.  The author wishes to express his 
gratitude to June Carbone, a friend and valued colleague, and organizer of the live symposium 
from which this article originated, “The Globalization of Pharmaceutical Development: Race, 
Markets, and Ethics, Santa Clara University School of Law, Mar. 16-17, 2006.  The author also 
would like to think his LSU Law Center colleagues for their valued thoughts, suggestions and 
care delivered in a faculty forum when this article was simply a presentation.  The comments of 
Lucy McGough, Jim Bowers, Alberto Zuppi, and Lee Ann Lockridge have been directly 
incorporated into this article.  This article also is part of a presentation made to the DePaul 
University College of Law and has been enriched by the comments received during that lively 
exchange. 
 
 1. See generally Centennial Symposium: Proceedings of “The Genomics Revolution?  
Science, Law and Policy,” 66 LA. L. REV. 1-143 (2005).  For a law-policy report on the 
general state of biotechnology in the U.S., see generally Michael J. Malinowski & Radhika 
Rao, Legal Limitations on Genetic Research and the Commercialization of Its Results, 54 
AM. J. COMP. LAW 45-65 (2006). 
 2. See generally JAMES D. WATSON, DNA: THE SECRET OF LIFE (Alfred A. Knopf ed., 2003); 
THE GENOMIC REVOLUTION: UNVEILING THE UNITY OF LIFE (Michael Yudell & Robert 
DeSalle eds., 2002) (concluding, “The knowledge gained [from Human Genome Project] 
could cure cancer, prevent heart disease, and feed millions. At the same time, its improper 
use can discriminate, stigmatize, and cheapen life through frivolous enhancement 
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of information technology and biotechnology.3  Bioinformatics accelerated the rate 
of completion of the map of the human genome by multiples during the final phase 
of the Human Genome Project (HGP)4 and, subsequently, capabilities have 
increased exponentially.  These bioinformatics capabilities and the quest to make 
medical sense out of the human genome are creating a potentially insatiable 
demand for access to human biological samples and accompanying medical 
information.5  In fact, demand has spilled over the borders of developed economies 
and is pouring into the world of developing economies.6 
Part II of this article surveys the forefront of biopharmaceutical research and 
development (“R&D”) with emphasis on the broadening reach into the global 
setting to gather human biological samples and accompanying medical 
information.7  Part III presents a case study involving a genetic research 
 
technologies.”); Allen Guttmacher & Francis Collins, Welcome to the Genomic Era, 349 
NEW ENG. J. MED. 996-98 (2004), available at http://www.nejm.org; Climbing the Helical 
Staircase: A Survey of Biotechnology, THE ECONOMIST, Mar. 29, 2003, at 1-24. 
 3. See generally ESSENTIALS OF GENOMICS AND BIOINFORMATICS (C.W. Sensen ed., 2005).  
For discussion of HGP, see generally 291 SCIENCE 1145 (Feb. 16, 2001) (issue entitled 
“The Human Genome”); 409 NATURE 745 (Feb. 15, 2001) (issue dedicated to the release of 
a draft map of the human genome).  Timely information about the genomics revolution may 
be obtained from the National Human Genome Research Institute (NHGRI), available at 
http:// www.nhgri.nih.gov. 
 4. Id. 
 5. See Paula Yoon, Risk Prediction for Common Diseases, 66 LA. L. REV. 33, 40 (2005).  See 
generally Symposium: Regulation of Biobanks, 33 J. L. MED. & ETHICS 1-188 (Mark 
Rothstein & Bartha Knoppers eds., 2005).  See also Malinowski & Rao, supra note 1, at 57-
58.  For discussion of the added dimension of ethical considerations associated with 
population genetics, including the concept of group consent, see generally Henry T. Greely, 
Informed Consent and Other Ethical Issues in Human Population Genetics, 35 ANNUAL 
REV. GENET. 785-800 (2001). 
 6. “The globalization of medical research is, in effect, quickly outpacing the development of 
internationally accepted ethical guidelines for the conduct of research.  For many medical 
researchers working in resource-poor countries, ethical decision-making is like sailing in 
the days before modern navigation; one is never quite sure where one is, or in what 
direction one is headed.”  Daniel W. Fitzgerald & Angela Wasunna, Away from 
Exploitation and Towards Engagement: An Ethical Compass for Medical Researchers 
Working in Resource-Poor Countries, 33 J.L. MED. & ETHICS 559, 559 (2005). 
 7. Although this article focuses primarily on basic research, much of its content also applies to 
clinical research, and the U.S. has been increasingly exporting human clinical trials to the 
world’s developing economies for some time.  See generally Finnuala Kelleher, Note: The 
Pharmaceutical Industry’s Responsibility for Protecting Human Subjects of Clinical Trials 
in Developing Nations, 38 COLUM. J. L. & SOC. PROBS. 67 (2004); Ruqaiijah Yearby, Good 
Enough to Use for Research, But Not Good Enough to Benefit From the Results of that 
Research: Are the Clinical HIV Vaccine Trials in Africa Unjust?, 53 DEPAUL L. REV. 1127 
(2004).  For discussion of how recruiting subjects is easier, quicker, and cheaper outside of 
the U.S., see generally William Dubois, New Drug Research, The Extraterritorial 
Application of FDA Regulations, and the Need for International Cooperation, 36 VAND. J. 
TRANSNAT’L L. 161 (2003); Joanne Roman et al., Note: U.S. Medical Research in the 
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undertaking in China by US interests — Millennium Pharmaceuticals, a 
Cambridge, MA-based biotech company, and Harvard University.8  This case 
study, though hopefully atypical, 9 illustrates the extent to which meaningful, 
reliable protection of human subjects does not exist in the global 
biopharmaceutical arena.  Part IV presents the governing law and policy, which is 
essentially questionable reliance on pilings of ethical guidelines in the absence of a 
bedrock of compulsory, enforceable law.  Part V introduces a range of proposals to 
sure up protection of human subjects in contemporary global biopharmaceutical 
R&D, including a proposal that works within the neoclassical economic theory 
 
Developing World: Ignoring Nuremberg, 11 CORNELL J.L. & PUB. POL’Y 441 (2002); Mary 
Pat Flaherty, et al., Testing Tidal Wave Hits Oversees; on Distant Shores, Drug Firms 
Avoid Delays—and Scrutiny, WASH. POST, Dec. 18, 2000, at A1; Margaret Wertheim, 
Medical Sweatshops: The Third World Is Providing a Cheap Source of Subjects for 
Research into AIDS and Other Conditions, GUARDIAN (LONDON), Oct. 5, 2000, at 3.  See 
also infra note 81. 
 8. See infra Part III and accompanying text.  This case study was one of several human 
subjects controversies in global biopharmaceutical R&D reported in “The Body Hunters,” a 
six-part Washington Post series published in December 2000 following an 11-month 
investigation by a team of journalists, which triggered more investigative journalism  and 
popular press coverage of controversies in global biopharmaceutical R&D, and a 28-page 
responsive report published by Pfizer, Inc. on its website (http://www.pfizer.com).  See Joe 
Stephens, Mary Pat Flaherty, Deborah Nelson, The Body Hunters, WASH. POST, Dec. 2000, 
available at http://washingtonpost.com/wp-dyn/world/issues/bodyhunters; Joe Stephens, 
Overseas Testing: Drug Firms Avoid U.S. Watchdogs by Using World’s Most Desperate, 24 
IRE J. 22 (June 30, 2001); David Warsh, Where the Germs Are, BOSTON GLOBE, Jan. 2, 
2001, at C1.  The controversies included Pfizer’s test of an unapproved antibiotic in 
seriously ill Nigerian children in the midst of a serious meningitis epidemic, use of placebos 
in AIDS studies in Thailand, and forged consent forms and patient deaths in a heart study 
done at the Naval Hospital in Buenos Aires.  See id.  For more coverage of such 
controversies, see also Fitzgerald & Wasunna, supra note 6, at 561-565; Flaherty, Testing 
Tidal Wave, supra note 7, at A1;Wertheim, Medical Sweatshops, supra note 7, at 3. 
 9. The team of reporters responsible for “The Body Hunters,” supra note 8, compiled a 
database of applications to the State Department to conduct federally funded clinical trials 
at overseas sites.  This database is being maintained by the Fogarty International Center at 
NIH.  See Stephens, Overseas, supra note 8.  (For information about the Fogarty 
International Center, visit its internet site at http://www.fic.nih.gov/.)  The Fogarty 
International Center resources provide some transparency in global clinical research.  The 
more comprehensive Bioresearch Monitoring Information System File, however, is limited 
to domestic trials known to the FDA; reporting is voluntary for overseas trials, and FDA 
only lists them in the database if researchers/sponsors submit resulting data to support a 
new drug application.  Stephens, Overseas, supra note 8.  For broader documentation of this 
pattern of exploitation, see Joe Stephens, Where Profits and Lives Hang in Balance: 
Finding an Abundance of Subjects and Lack of Oversight Abroad, Big Drug Companies 
Test Offshore to Speed Products to Market, WASH. POST, Dec. 17, 2000, at A1.  For 
discussion of the need to establish a conclusive registry, see generally Jennifer M. Gold & 
David M. Studdert, Clinical Trials Registries: A Reform that is Past Due, 33 J. L. MED. & 
ETHICS 811 (2005). 
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promoted forcefully by the US in the enactment and implementation of the Trade 
Related Intellectual Property Rights (TRIPS) provisions of the General Agreement 
on Tariffs and Trade (GATT).10  The article concludes that the US has the 
responsibility and capability to realize reliable human subject protections in 
international biopharmaceutical R&D as a complement to the patent regime 
baseline established by GATT/TRIPS. 
II.  The Global Forefront of Biopharmaceutical R&D 
A major theme of the Human Genome Project (HGP) was genetic sameness: we 
are all 99.9 percent the same in terms of the billions of base pairs — the As, Cs, 
Gs, and Ts that form our DNA11 — that constitute the basic molecular formula for 
each of us.12  Perhaps the most important finding of HGP to date is that all human 
diversity is attributable to just 25,000 or less active genes.13  Yet, one need only 
ride the New York City subway a few stops or people watch in Time Square to 
witness just how diverse we are, especially for such a young species.  So, how do 
we resolve our genetic sameness with tangible human diversity? 
The answer is that genes multitask with dimensions of complexity a universe 
beyond the appreciation of most at the commencement of HGP.14  So, ironically, 
the awesome accomplishment of HGP is extremely humbling.  Nevertheless, by 
opening up a gateway of understanding and vision, HGP has brought human health 
science to a new beginning: 
Reminiscent of Galileo pointing his telescope into the sky and discovering celestial “new 
lands,” contemporary scientists are using bioinformatics to peer into the human genome.  
They are beginning to truly comprehend the extent to which the human genome is a 
universe that encompasses voluminous multitasking and innumerable layers of dynamic 
intricacy.  Consequently, the science community and pharmaceutical and biotechnology 
 
 10. See infra notes 84-91 and accompanying text. 
 11. These letters stand for the nucleotides adenine, thymine, cytosine, and guanine.  
Information about the basics of DNA is available at the internet sites of the National 
Institutes of Health, http://www.history.nih.gov/exhibits/genetics/sect1.htm, and the 
National Human Genome Research Institute, and see The Human Genome Project, 
Timeline: 1953 – DNA Double Helix, 
http://www.genome,gov/Pages/Education/Kit/main.cfm?pageid=31 (last visited Nov. 4, 
2006). 
 12. Prof. Troy Duster, Dinner Presentation, “The Globalization of Pharmaceutical 
Development: Race, Markets and Ethics” (Mar. 16, 2006) (addressing the “shift from 
genetic sameness to individuality” pre- and post-HGP) (copy on file with author). 
 13. J. Michael McGinnis, Population Health and the Influence of Medical and Scientific 
Advances, 66 LA. L. REV. 9, 10 (2005). 
 14. Id. at 10. (Estimates prior to the final phase of HGP generally ranged from 100,000 to 
150,000 genes.) 
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sectors are more fully appreciating, and realizing, the difficulty of crafting market-scale 
medical applications from genetic knowledge.15 
In hindsight, HGP was a potential “white elephant” at its commencement, for 
the enabling technology necessary for its completion was an information 
technology revolution beyond existing capabilities.16  Fortunately, information 
technology accomplishments in the mid and late 1990s made HGP achievable 
years ahead of schedule.17  Subsequently, silicon microchip technology has 
advanced so as to allow researchers to fit the entire human genome on a single 
piece of silicon held easily in the palm of a human hand.18  Scientists are utilizing 
this capacity to make voluminous, timely sample comparisons to translate the map 
of the human genome into medical meaning.19  Appreciation of the intricacies of 
the human genome coupled with bioinformatics capabilities has created ravenous 
demand for human biological samples and accompanying medical information.  As 
observed by Dr. Paula Yoon at the CDC’s Office of Genomics and Disease 
Prevention, “[w]e need large-scale, population-based collaborative research 
because, when you start looking at multiple genes and multiple environmental 
factors to stratify risks, you need big numbers to find meaningful associations.”20  
The result is global demand for samples, biobanking, the organized collection of 
human biological samples and accompanying medical information, is burgeoning 
in response.21 
 
 
 
 15. Michael J. Malinowski, Taking Genomics to the BioBank: Access to Human Biological 
Samples and Medical Information, 66 LA. L. REV. 43, 45 (2005). 
 16. Id. at 45. 
 17. “In 1997, HGP was half-way through its 15-year duration and 90% of the project’s funding 
had been spent just to sequence accurately 2.68% of the human genome.”  Michael J. 
Malinowski, Separating Predictive Genetic Testing from Snake Oil: Regulation, Liabilities, 
and Lost Opportunities, 41 JURIMETRICS J. 23, 26 (2000).  The author was working for the 
Massachusetts Biotechnology Council and then in private practice at this time in Boston 
and, ironically, from an investment competition perspective, information technology was 
the arch nemesis of biotechnology. 
 18. Robert Wells, Intellectual Property/Ownership Issues, 66 LA. L. REV. 69, 73 (2005). 
 19. See generally id. 
 20. Yoon, Risk Prediction, supra note 5, at 40. 
 21. See generally Symposium, Biobanks, supra note 5; Malinowski, BioBank, supra note 15. 
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III.  The Harvard University-Millennium Pharmaceuticals 
Controversy 
In 1996, China passed a law to promote sterilization or, alternatively, life-long 
birth control for individuals with “genetic disease(s) of a serious nature.”22  Just a 
month later, Harvard University, through its affiliates, the Harvard School of 
Public Health and Brigham and Women’s Hospital in Boston, Massachusetts, 
coupled with Millennium Pharmaceuticals, the Massachusetts Mental Health 
Center, and the Government of China and Chinese field researchers to launch a 
genetic research study in Anhui, a rural province in China. 23 This population was 
especially appealing for genetic research because poverty and geography has kept 
the people isolated for over 2,000 years.24  This study encompassed a bouquet of 
health conditions ranging from obesity to schizophrenia.25 
 In 1999, Gwendolyn Zahner, a psychiatric epidemiologist and former 
assistant professor at the Harvard School of Public Health, filed a fifteen-page 
complaint with the US Office for the Protection of Human Research Participants 
(OHRP) alleging that two occupational epidemiologists at the school had taken 
advantage of the subjects in this study.26  OHRP launched an investigation in 1999, 
which lingered into 2002.27  The investigation generated damning findings, 
foremost of which was that coercion was used to recruit subjects.28  The report 
addressed nearly a dozen studies overseen by Dr. Ming T. Tsuang.29  The Harvard-
Millennium research study had been deemed a “thought works” project,30 and 
 
 22. Joe Stephens, Overseas Testing, supra note 8; John Pomfret & Deborah Nelson, An Isolated 
Region’s Genetic Mother Lode; Harvard-Led Study Mined DNA Riches; Some Donors Say 
Promises Were Broken, WASH. POST, Dec. 20, 2000, at A1; Alice Dember, Harvard-
Affiliated Gene Studies in China Face Federal Inquiry, BOSTON GLOBE, Aug. 1, 2000, at 
A1. 
 23. See Correspondence from Kristina C. Borror, Compliance Oversight Coordinator, Division 
of Compliance Oversight, to Ming T. Tsuang, Head, Harvard Department of Psychiatry, 
Massachusetts Mental Health Center (Mar. 28, 2002) (copy on file with author).  See also; 
Andrew Lawler, U.S. Questions Harvard Research in China, 296 SCIENCE 28, Apr. 5, 2002 
(no author identified); Esther Chang, Fitting a Square Peg Into a Round Hole?: Imposing 
Informed Consent and Post-Trial Obligations on United States Sponsored Clinical Trials in 
Developing Countries, 11 S. CAL. INTERDISC. L.J. 339, 346-47; Pomfret & Nelson, supra 
note 22, at A1; Dember, Studies in China, supra note 22. 
 24. Stephens, Overseas Testing, supra note 8. 
 25. Dember, supra note 22, at A1. 
 26. Id.  See also Lawler, supra note 23, at 28. 
 27. See generally Correspondence, supra note 23. 
 28. Id.  Communication challenges were underscored, including language and cultural barriers.  
See also Chang, supra note 23, at 346-47. 
 29. Dember, supra note 22, at A1. 
 30. The legacy of thought works projects included penalties for refusal to participate — such as 
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Chinese government officials organized local cadres to encourage the needed DNA 
collection.31  At the time of the study, China’s free health care system had 
collapsed,32 and study participants were offered health care, including access to 
exams, test results, follow-up care, and “health cards” for discounts on future 
treatment.33  People literally gave blood and medical information as a quid pro quo 
for this immediate care and the promise of long-term treatment ensured through 
coupons redeemable at local clinics.34  Unfortunately, these local clinics never 
were funded, and the long-term care  never wasrealized.35 
When the OHRP findings were revealed, the immediate concern was fear of 
genetic discrimination given China’s policy on reproduction and genetic diseases 
juxtaposed with the government’s role in the study and its dismal human rights 
legacy.  An additional concern was the fact that much of the actual work in the 
study was carried out by citizens of China while the principal investigators resided 
thousands of miles away in Cambridge, Massachusetts.36  The defense raised by 
the researchers was that the samples were encrypted, and the code to break the 
encryption was beyond the reach of China’s government officials.37  Nevertheless, 
concerns were heightened by the discovery that many of the subjects’ written 
consent forms had been backdated; the dates on the forms were written in identical 
third-party handwriting.38  Moreover, Brigham and Women’s Hospital and the 
Massachusetts Mental Health Center had delegated oversight of human subjects 
protection to an oversight committee in China.39  Brigham & Women’s admitted 
 
negative tax consequences, land divisions, and other pressures.  Chang, supra note 23, at 
346-47.  Positive incentives also had been utilized — for example, in another one of Dr. 
Ming T. Tsuang’s studies, to encourage participation in a study on reproduction that 
encompassed 1000 women working at a petrochemical plant in Beijing.  Id.  According to 
Dr. Ock Joo Kim, a Professor at the College of Medicine, Seoul National University, and a 
fellow panelist at this live symposium, this reproduction study also was headed by Dr. 
Ming. T. Tsuang.  Presentation by Dr. Ock Joo Kim, Panel III: Ethics in a Global 
Pharmaceutical Environment, 5th Annual Biotechnology Conference — The Globalization 
of Pharmaceutical Development: Race, Markets and Ethics, Mar. 17, 2006. 
 31. Dember, supra note 22, at A1; Lawler, supra note 23, at 28. 
 32. Chang, supra note 23, at 346-347.  See also Dember, supra note 22, at A1; Lawler, supra 
note 23, at 28. 
 33. Chang, supra note 23, at 346-47. 
 34. Id. 
 35. Id. 
 36. Dember, Studies in China, supra note 22, at A1; U.S. Questions, supra note 23, at 28. 
 37. Dember, supra note 22, at A1. 
 38. Lawler, supra note 23, at 28. 
 39. Dember, supra note 22, at A1. 
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that they had been derelict in this delegation of oversight.40 
Harvard responded to the inquiry and to OHRP’s findings by announcing a 
commitment to increase the monitoring of its staff and by issuing a formal 
reprimand of the two key researchers involved.41  To the disappointment of many, 
OHRP accepted this response as a resolution of the matter.42 
IV.  Existing Law-Policy to Protect Human Subjects in Global 
R&D 
What conditions allowed the Harvard-Millennium controversy to occur?  The 
summary answer is that there is no compulsory, enforceable international law to 
protect human subjects.43  Rather, there are ethical guidelines, the most influential 
of which are (1) the Nuremberg Code,44 (2) the Declaration of Helsinki,45 and (3) 
Guidelines for Medical Ethics in Biomedical Research issued jointly by the World 
Health Organization and the Council for International Organizations of Medical 
Sciences (CIOMS).46  The Nuremberg Code, issued in 1947 in response to the 
gruesome atrocities deemed “Nazi medicine,”47 consists of ten principles that are 
 
 40. Id.  See also Lawler, supra note 23, at 28. 
 41. Lawler, supra note 23, at 28.  (The primary researcher, Dr, Tsuang, now is a member of the 
faculty of the University of California at San Diego, and his research continues.  UCSD 
News, May 21, 2003, available at http://health.ucsd.edu/news/2003/05_21_Tsuang.html.) 
 42. Lawler, supra note23, at 28. 
 43. See generally Yearby, supra note 7; Benjamin Mason Meier, International Criminal 
Prosecution of Physicians: A Critique of Professors Annas and Grodin’s Proposed 
International Medical Tribunal, 30 AM. J.L. & MED. 419 (2004); Roman, supra note 7. 
 44. TRIALS OF WAR CRIMINALS BEFORE THE NUREMBURG MILITARY TRIBUNALS UNDER 
CONTROL COUNCIL LAW NO. 10, 181-83 (U.S. Gov’t Printing Office 1946-1949).  See 
generally Leanord H. Glantz, The Influence of the Nuremberg Code on U.S. Statutes and 
Regulations, in THE NAZI DOCTORS AND THE NUREMBERG CODE 183 (George Annas & 
Michael A. Grodin eds., 1992). 
 45. WORLD MED. ASS’N, WORLD MEDICAL ASSOCIATION THE DECLARATION OF HELSINKI: 
ETHICAL PRINCIPLES FOR MEDICAL RESEARCH INVOLVING HUMAN SUBJECTS PRINCIPLE 
(adopted 1964, revised 2002), available at http://www.wma.net/e/policy/b3.htm. 
 46. COUNCIL FOR INT’L ORGANIZATIONS OF MEDICAL SCIENCES, INT’L ETHICAL GUIDELINES 
FOR BIOMEDICAL RESEARCH INVOLVING HUMAN SUBJECTS (Geneva: CIOMS, 1993), 
available at  (3d ed. 2002), available at http://www.cioms.ch/frame_guidelines_ 
nov_2002.htm  (last visited Nov. 26, 2005).  These guidelines were introduced with the 
hope of introducing pragmatic rules  in lieu of the amorphous informed consent standards of 
the Code.  See Roman, supra note 7. 
 47. JOHN J. MICHALCZYK, NAZI MEDICINE: IN THE SHADOW OF THE REICH (First Run Features 
1997) (discussing the origins of eugenics movements in Germany and the Nazi doctors' 
experimentation on prisoners in the concentration camps).  See generally INT’L AUSCHWITZ 
COMMITTEE, NAZI MEDICINE: DOCTORS, VICTIMS AND MEDICINE IN AUSCHWITZ (1986) 
(documenting the criminal experiments undertaken by the Nazi doctors); ROBERT JAY 
LIFTON, THE NAZI DOCTORS: MEDICAL KILLING AND THE PSYCHOLOGY OF GENOCIDE 
(1986) (examining the Nazi “biomedical vision” as evidenced by the doctors’ cruel medical 
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centered on the doctrine of informed consent.48  The Code was never adopted by 
the United Nations as an instrument of international law.49  Moreover, the reach of 
international criminal law extends only as far as the codification of victim rights by 
nations and international tribunals, and “[i]nternational law remains ambiguous in 
its prohibitions of physician participation in corporal and capital punishment or 
physician discrimination in the provision of health services.”50  Similarly, the 
applicability of international tort liability in this context is a hazy shadow at best 
and, as a policing mechanism, tort liability places a tremendous burden on 
populations already extraordinarily overwhelmed with challenges.51 
The Declaration of Helsinki, issued in 1964 and revised through 2000, is the 
medical profession’s effort to apply the Nuremberg Code to the practice of 
medicine and to generate some broad-reaching practical guidelines.52  The 
 
experiments in the concentration camps); THE NAZI DOCTORS AND THE NUREMBERG CODE 
(George J. Annas & Michael A Grodin eds., 1992) (discussing the practices of the Nazi 
doctors that led to the Nuremberg trial and the implications of these practices on present 
day medical research and experimentation). 
 48. TRIALS OF WAR CRIMINALS, supra note 44. 
 49. See Kevin M. King, Note, A Proposal for the Effective International Regulation of 
Biomedical Research Involving Human Subjects, 34 STAN. J. INT’L L. 163, 169 (1998). 
 50. Benjamin Mason Meier, International Criminal Prosecution of Physicians: A Critique of 
Professors Annas and Grodin’s Proposed International Medical Tribunal, 30 AM. J.L. & 
MED. 419, 421 (2004).  As explained by one commentator, international criminal law is just 
beginning to crystallize in a potentially relevant context:  “ On July 17, 1998, representatives 
of more than 160 nations met in Rome, Italy and adopted an international treaty to govern a 
permanent international criminal court, the Rome Statute of the International Criminal 
Court (“Rome Statute”).  The ICC, created by the Rome Statute, has subject matter 
jurisdiction over the so-called ‘core crimes’ of genocide, crimes against humanity, war 
crimes, and, once defined, aggression.  Within this jurisdiction will fall crimes committed 
by physicians and non-physicians alike.  This permanent criminal court, built upon the ad 
hoc tribunals of Nuremberg and beyond, came into effect in 2002 and has just begun to 
adjudicate its first case.”  Id. at 420 (internal citations omitted).  (Professors Annas and 
Grodin have proposed, since at least 1992, that an International Medical Tribunal be 
established to develop international criminal law in the field of medicine.  See generally 
George J. Annas & Michael A Grodin, Medical Ethics and Human Rights: Legacies of 
Nuremberg, 3 HOFSTRA L. & POL’Y SYMP. 111, 119 (1999).) 
 51. The Bush Administration has argued vigorously that the vehicle for such liability, the Alien 
Tort Claims Act, interferes with the executive prerogative in foreign affairs, and that from a 
legal standpoint the statute grants federal courts jurisdiction but does not grant plaintiffs a 
private cause of action.  See Lorelle Londis, The Corporate Face of the Alien Torts Claims 
Act: How an Old Statute Mandates a New Understanding of Global Interdependence, 57 
ME. L. REV. 141, 143 (2005). 
 52. Helsinki II is widely received as the baseline set of principles for human subjects research.  
See Rebecca A. Finkenbinder, New Recommendations on International Human Research: 
Can Minimum Standards Prevent the Exploitation of Vulnerable Human Subjects in 
Developing Countries, 21 PENN. ST. INT’L L. REV. 363, 373 (2003). 
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Declaration is the work product of the World Medical Association (WMA), which 
came into existence as the medical profession’s response to Nazi Medicine and the 
threat of extensive regulation from outside of the profession.53  The Declaration 
focuses on the duties and responsibilities of physicians engaging in research on 
human subjects, and it assumes a virtual common denominator: adherence to 
“generally accepted scientific principles.”54  An obvious question is “whose 
generally accepted scientific principles?”  Also, the US has not signed onto the 
2000 Declaration revisions, and these revisions are being challenged by the US 
Food and Drug Administration (FDA).55  The FDA does not want standards that 
require researchers to give back to study participants or that require making study 
medicines available to all participants, including those outside of the US borders, 
once their effectiveness and safety are established beyond the placebo effect.56 
Perhaps the most meaningful guidance is the Guidelines for Medical Ethics in 
Biomedical Research issued in 1982 jointly by the WHO and the Council for 
International Organizations of Medical Sciences (CIOMS).57  The goal in issuing 
the Guidelines was to introduce rules more specific than the Code’s amorphous 
informed consent provisions.58  However, the Guidelines are not legal text in 
content.  Rather, they articulate three principles — respect for persons, 
beneficence, and justice — captured earlier in the US’s Belmont Report, which 
emphasizes informed consent and the need for research to be responsive to the 
health needs and priorities of the community in which it is carried out. 59 
 
 53. Meier, supra note 50, at 423. (“In the aftermath of the Nazi horrors, physicians from thirty-
two national medical associations met in London in 1946 to form the first international 
medical organization, the World Medical Association (‘WMA’).  The WMA has since 
burgeoned to become the world’s preeminent physician organization.”). 
 54. Declaration of Helsinki Principle I.1, II.2, II.3, in Office for Human Research Protections, 
Department of Health and Human Services, Institutional Review Boards (IRB) Guidebooks, 
App. 6 (1993). 
 55. John Barton, Keynote Address at the Santa Clara Univ. School of Law Annual 
Biotechnology Conference: The Globalization of Pharmaceutical Development: Race, 
Markets and Ethics (Mar. 17, 2006). 
 56. Id. 
 57. CIOMS was organized in 1949 by WHO and UNESCO.  See generally Markus Schott, 
Medical Research on Humans: Regulation in Switzerland, the European Union, and the 
United States, 60 FOOD & DRUG L.J. 45, 50 (2005).  (More information about CIOMS is 
available at http://www.cioms.ch/.) 
 58. See Schott, supra note 57, at 64. 
 59. See The Belmont Report, 44 Fed. Reg. 23192, 23192-93 (Apr. 18, 1979).  The Belmont 
Report was issued in 1977 by the National Commission for the Protection of Human 
Subjects of Biomedical and Behavioral Research which was established in 1974 by the 
National Research Act.  See Roman, supra note 7, at 456.  The Guidelines incorporate the 
three Belmont Report principles: respect for persons, beneficence, and justice.  See Yearby, 
supra note 7, at 1128. 
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The net effect of international law is that the protection of human subjects in 
global biopharmaceutical R &D depends upon national law — the law of the 
jurisdiction in which the research is conducted60 and the law of the homeland of 
those conducting the research study.61  Commentators have recognized the 
following regarding the law of the jurisdiction in which the research is conducted: 
With biomedical research becoming increasingly global, research volunteers in resource-
poor countries may be at a heightened risk of exploitation.  As the number of new drugs 
and products entering clinical trials grows, so does the need to find clinical sites capable of 
conducting research quickly and inexpensively. Therefore, research sponsors may be 
attracted to resource-poor countries where a large population of people with high disease 
burden may serve as research volunteers, where access to patients may be easier due to 
fewer competing clinical trials and lax regulation, where patients may not have access to 
medications and hence may be drug naive, and where lower personnel costs may make the 
research less expensive.  Potential research volunteers in resource-poor countries, who are 
poor, illiterate, and unfamiliar with their rights as research volunteers may thus be 
vulnerable to exploitation by international medical researchers and research sponsors.62 
In the context of the Harvard-Millennium controversy, the government of China 
with its preexisting eugenics policy, legacy of human rights violations, and 
aggressive promotion of genetic research within its borders, was not a reliable 
source of meaningful human subjects protection.63  Thus, the OHRP investigation 
focused on “the extent to which the Harvard-Millennium controversy violated 
national US law.” 
The primary bodies of US law created to protect human subjects are the 
Common Rule64 and Food and Drug Administration regulations.65  The Common 
 
 60. See Dubois, supra note 7, at 190.  See generally Dubois, New Drug Research, supra note 7.  
It is commonplace for countries to relax US standards, making trials abroad usually quicker 
and cheaper. 
 61. Lisa R. Pitler, Ethics of AIDS Clinical Trials in Developing Countries: A Review, 57 FOOD 
& DRUG L.J. 133, 152 (2002).  See generally Roman, supra note 7; Barbara A. Noah, 
Racial Disparities in the Delivery of Health Care, 35 SAN DIEGO L. REV. 135 (1998). 
(National Bioethics Advisory Commission, Ethical and Policy Issues in International 
Research: Clinical Trials in Developing Countries, available at 
http://www.georgetown.edu/research/nrcbl/nbac/clinical/execsum.html).  
 62. Fitzgerald & Wasunna, supra note 6, at 559-60 (2005) (footnotes omitted). 
 63. Dember, supra note 23, at A1. 
 64. 45 C.F.R. Part 46 (2005). 
 65. The relevant FDA regulations are 21 C.F.R. Part 56 (2006) (IRB rules); 21 C.F.R. Part 50 
(2006) (informed consent rules).  For guidance on both the Common Rule and FDA 
regulations, see generally CARL H. COLEMAN, ET AL., THE ETHICS AND REGULATION OF 
RESEARCH WITH HUMAN SUBJECTS (2005).  Excellent, pragmatic “decision trees” and 
other guidance for applying U.S. regulations to protect human subjects are available at 
NIH’s internet site, www.nih.gov. 
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Rule applies to all federally funded research and often is stretched to cover all 
research undertaken by institutions that receive federal funding — meaning 
institutions such as Harvard University, which routinely ranks among the top 
recipients of National Institutes of Health (NIH) funding.66  To comply, institutions 
must establish institutional review boards (IRBs), policies, and implementation 
procedures to ensure that requisite oversight and prescribed requirements are 
realized.67  Moreover, institutions must report the same to OHRP to obtain an 
Assurance of Compliance, a prerequisite for receiving federal funding, and provide 
periodic updates.68 
The FDA, gatekeeper to the US market for food and medicinal products, allows 
and oversees limited access to the population entrusted to its watch to enable 
research with the purpose of establishing safety and efficacy for potentially 
marketable products.69  Independently of the Common Rule but in a parallel 
fashion, the FDA makes compliance with its human subjects regulations a 
condition on the research it permits to take place via an Investigational New Drug 
Application (IND) or an Investigational Device Exemption (IDE).70  Moreover, 
confirmation of compliance is a condition for acceptance of data in support of 
applications for market access.71  The FDA also conditions acceptance of data 
 
 66. Harvard ranked 12th in 2005 NIH grants to domestic institutions of higher education.  
Available at http://grants2.nih.gov/grants/award/trends/dheallinst05.htm. 
 67. COLEMAN, supra note 65, at 169-202. 
 68. 45 C.F.R. Part 46, §103(a).  Registration must be updated every thirty-six months.  Id.  See 
COLEMAN, supra note 65, at 169-202. 
 69. For information about the FDA and its regulations, visit www.fda.gov. 
 70. COLEMAN, supra note 65, at 142-60. 
 71. The Common Rule requires the sixteen participating agencies to confirm that institutions 
conducting the research they fund, including institutions outside of the US, comply with the 
human subject protections it prescribes or one of the following: INT’L CONFERENCE ON 
HARMONISATION, GUIDELINES FOR GOOD CLINICAL PRACTICE E6(R1), CONSOLIDATED 
GUIDELINE (1996), available at http://www.ich.org/LOB/media/MEDIA482.pdf; COUNCIL 
FOR INT’L ORGANIZATIONS OF MEDICAL SCIENCES, INT’L ETHICAL GUIDELINES FOR 
BIOMEDICAL RESEARCH INVOLVING HUMAN SUBJECTS (1993), available at  
http://www.codex.uu.se/texts/international.html.  Updated version available at 
http://www.cioms.ch/frame_guidelines_nov_2002.htm; MEDICAL RESEARCH  OUNCIL OF 
CANADA, TRI-COUNCIL POLICY STATEMENT ON ETHICAL CONDUCT OF RESEARCH 
INVOLVING HUMANS (2005), available at 
http://www.pre.ethics.gc.ca/english/pdf/TCPSintroductione.pdf; INDIAN COUNCIL OF 
MEDICAL RESEARCH, ETHICAL GUIDELINES FOR BIOMEDICAL RESEARCH ON HUMAN 
SUBJECTS (2000), available at http://www.icmr.nic.in/ethical.pdf; or other “internationally 
recognized standards.”  See Department of Health and Human Services, 45 C.F.R.§ 46 
(2005).  Sponsors of market applications for new products are technically required to 
identify all clinical investigators who conducted clinical trials of the product (including 
employees and non-employees of the company) and to submit a certification that discloses 
any of the following financial arrangements: compensation affected by the outcome of the 
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gathered outside the US on compliance with US regulations or the International 
Conference on Harmonisation Guidelines for Good Clinical Practice.72  However, 
in reality, the US tends to defer heavily to the laws and regulations of the country 
in which the research is conducted.73  Moreover, the “U.S. has no clear 
enforcement mechanisms for its research guidelines”74 and the “FDA currently 
lacks any way to track the total number of experiments conducted abroad, nor can 
it determine the number of new drugs that are approved on the basis of foreign 
clinical research.”75 
In addition to these standard human subject protections, the Common Rule 
compels IRBs to police conflicts of interest (CIs), and specific Public Health 
Services and FDA regulations directly address CIs and require the same.76  
Accordingly, in addition to IRBs, many federally funded research institutions have 
committees that focus on conflicts of interest and operate in conjunction with 
IRBs.  Moreover, today, collaboration often is synonymous with meaningful 
research.  The Harvard-Millennium controversy is representative of many 
contemporary research undertakings in that multiple institutions were involved, 
including a commercial sponsor removed from US federal funding and related 
requirements.  Also, as illustrated by the Harvard-Millennium case study and 
substantiated by Brigham & Women’s admission, it is too easy for an institution to 
remain compliant, technically, with OHRP requirements, but delegate oversight to 
a collaborator.77 
 
 
study, significant equity interest in the sponsor of the study, proprietary interest in the tested 
product, and significant payments of other types from the sponsor.  21 C.F.R. § 54.4(a)(3)(i-
v)(2006). 
 72. Int’l Conference on Harmonisation, GUIDELINES FOR GOOD CLINICAL PRACTICE E6(R1), 
CONSOLIDATED GUIDELINE (1996). 
 73. See generally Lisa R. Pitler, Ethics of AIDS Clinical Trials in Developing Countries: A 
Review, 57 FOOD & DRUG L.J. 133 (2002).  See, e.g., Dubois, supra note 7, at 170. 
 74. Finkenbinder, supra note 52, at 387. 
 75. Dubois, supra note 7, at 168. 
 76. Financial Relationships and Interests in Research Involving Human Subjects: Guidance for 
Human Subject Protection, 69 Fed. Reg. 26,393 (May 11, 2004); Food and Drug 
Administration, 21 C.F.R. § 54.4 (2003); IRB Member Conflicts of Interest, 45 C.F.R. § 
46.107(e).  See COLEMAN, supra note 65, at  207-39.  Note, however, that the FDA waives 
conflicts of interest for members of its advisory committees where interests do not exceed 
$100,000.  See www.fda.gov/fdac/special/newdrug/advice.html. 
 77. See generally Roman, supra note 7. 
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V.  A Proposal to Do More 
Research may prove a point of entry for countries left out of the genomics 
revolution, but “it is neither necessary nor desirable to relax our ethical standards 
in order to achieve this goal.”78  As illustrated by the Harvard-Millennium case 
study and related controversies,79 the global reach and existing research needs of 
biopharmaceutical R&D demand a baseline of compulsory, enforceable 
international human subjects protection regulations — meaning codification of 
shared global standards with an effective enforcement mechanism.80 
One option is to develop such law through the establishment and proceedings of 
an International Medical Tribunal, as proposed by Professors Annas and Grodin, 
beginning close to the commencement of HGP.81  Another is to build upon an 
already existing mechanism — the International Conferences on Harmonisation 
(ICHs), which have developed shared scientific standards for clinical data and 
good clinical practice.82  However, ICH is representative of global 
biopharmaceutical R&D, meaning that the world’s dominant commercial interests 
comprise half of its sponsors and more than half of its Steering Committee 
members.83  Those interests are unlikely to voluntarily support the introduction of 
 
 78. Harold P. Shapiro & Eric M. Meslin, Ethical Issues in the Design and Conduct of Clinical 
Trials in Developing Countries, 345 NEW. ENG. J. MED. 139, 141 (2001). 
 79. See supra notes 6-8. 
 80. See generally Symposium: Emerging Issues in Population Health: National and Global 
Perspectives, 314 J.L. MED. & ETHICS 473 (2003); Roman, supra note 7; Benjamin Mason 
Meier, Int’l Protection of Persons Undergoing Medical Experimentation: Protecting the 
Right of Informed Consent, 20 BERKELEY J. INT’L L. 513, 514 (2002); Paul Farmer & 
Nicole Gastineau Campos, Symposium: Looking Forward in Bioethics, New Malaise: 
Bioethics and Human Rights in the Global Era, 32 J.L. MED. & ETHICS 232 (2003).  WHO 
has responded by developing twenty standards to improve reporting on human subject 
testing of drugs and devices.  See Lawrence K. Altman, Science and Health, N.Y. TIMES, 
May 19, 2006, at A10.  For more information, visit the site of WHO at 
http://www.who.int/enl. 
 81. See supra note 50 and accompanying text.    
 82. Id.  For information about ICH, visit the Official Web Site for ICH, 
http://www.ich.org/cache/compo/276-254-1.html.  Six conferences have been held, and the 
ICH7 Conference was scheduled to take place March 29-30, 2006 in Vienna, Austria, but 
was cancelled.) 
 83. Presentation, Barton, supra note 55.  (Both government and industry have been active 
participants in the ICHs.  The US has been represented by both the FDA and the 
Pharmaceutical Researchers and Manufacturers of America (PhRMA), Europe has been 
represented by the European Medicines Evaluation Agency (EMEA) and the European 
Federation of Pharmaceutical Industries Associations (EFPEA), and Japan has been 
represented by the Ministry of Health, Labor and Welfare and the Japan Pharmaceutical 
Manufacturers Association (JPMA).  In addition, to the representatives of these six 
sponsors, the Steering Committee includes members of the International Federation of 
Pharmaceutical Manufacturers Associations (IFPMA) and observers from Health Canada, 
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meaningful additional regulatory requirements and associated liabilities. 
A third option is to draw from recent experience establishing a global common 
denominator in intellectual property rights through the Technology Related 
Intellectual Property Rights (TRIPS) of the General Agreements of Tariffs and 
Trade (GATT), which has been implemented in phases since its enactment on 
January 1, 1995.84  Commercial interests, including the biopharmaceutical sectors, 
drove the GATT/TRIPS efforts with the mantra of establishing a baseline of 
enforceable IP rights essential to break down market impediments, advance market 
access, and promote globalization.85  GATT/TRIPS is the embodiment of 
neoliberal economic theory premised on the claim that economic liberalization will 
promote growth and reduce poverty in countries with developing economies.86  To 
the extent that there is truth to the theory,87 GATT/TRIPS should increase the 
presence of biopharmaceutical R&D in developing economies and should build 
upon the existing need for a shared, compulsory, and enforceable international 
standard for the protection of human subjects — a need already realized as 
illustrated by the Harvard-Millennium controversy and related controversies, as 
 
the World Health Organization, and Swissmedic, Swiss Agency for Therapeutic Products. 
ICH Official Web Site, supra note 79.) 
 84.  Countries deemed “developing” were given until January 2000 to comply, and “least 
developed countries” were given until 2005.  Puleng LenkaBula, The Social and Ethical 
Implications of Article 27 of the Agreement on Trade Related Aspects of Intellectual 
Property Rights (TRIPS) on African Communities, Biodiversity and Indigenous Knowledge, 
J. THEOLOGY S. AFR., vol. 36, July 1, 2005, WLNR 16456512.  For discussion of the 
provisions of TRIPS, the protections it affords patent holders, and the negotiations leading 
to its adoption, see generally Vishal Gupta, A Mathematical Approach to Benefit - 
Detriment Analysis as a Solution to Compulsory Licensing of Pharmaceuticals Under the 
TRIPS Agreement, 13 CARDOZO J. INT'L & COMP. L. 631, 636-42 (2005); John Gladstone 
Mills et al., Patent Law Basics § 19:4.1 (2006) (a general discussion of the World Trade 
Organizations (WTO) TRIPS agreement and WTO dispute resolutions); Donald P. Harris, 
TRIPS Rebound: An Historical Analysis of How the TRIPS Agreement Can Ricochet Back 
Against the United States., 25 NW. J. INT'L L. & BUS. 99, 101 (2004). 
 85.  See generally Christopher K. Eppich, Patenting Dilemma: Drugs for Profit Versus Drugs 
for Health, 43 SANTA CLARA L. REV. 289 (2002); Bryan C. Mercurio, TRIPS, Patents, and 
Access to Life-Saving Drugs in the Developing World, 8 MARQ. INTELL. PROP. L. REV. 21 
(2004). 
 86.  See generally Mohammed Nuruzzaman, Economic Liberalization and Poverty in the 
Developing Countries, 35 J. CONTEMP. ASIA 109, 109 (Mar. 1, 2005); A. Berg & A. 
Krueger, Lifting All Boats: Why Openness Helps Curb Poverty, 39 FIN. & DEV. 16 (2002); 
Ian Vasquez, Globalization and the Poor, 7 INDEP. REV. 197 (2002). 
 87.  For an argument that the theory is flawed based upon empirical data on the impact of 
economic liberalization on countries with developing economies, see generally 
Nuruzzaman, supra note 86. 
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well as the recent WHO response.88  A reliable international common denominator 
for the protection of human subjects would be a natural R&D complement to the 
global IP baseline established by GATT/TRIPS.  Moreover, such a standard would 
be consistent with specific GATT/TRIPS provisions, as well as its spirit and intent 
to promote globalization.  The US was highly influential in establishing the basic 
patent regime criteria codified in TRIPS, but the US practice of minimizing 
morality considerations in patent prosecution was trumped by European IP 
standards that place a morality check on patentability.  Specifically, Articles 27.2 
and 27.3 of TRIPS allow for IP rights to be overridden “to protect the public order, 
morality, animal or plant health/life, the environment; may exclude diagnostics, 
therapeutics and surgical methods of treatment of humans and animals from 
patentability.”89  Moreover, the TRIPS patent regime bends to allow nations to 
respond to health emergencies.  Under Article 31, a WTO member may grant the 
use of the subject matter of the patent without the consent of the patent holder 
through compulsory licensing to meet urgent health care needs.90  Perhaps, over 
 
 88.  See supra Parts III & IV. 
 89.  These provisions are consistent with Article 53(a) of the European Patent Convention and 
the European Biotechnology Directive.  See Convention on the Grant of European Patents, 
Oct. 5, 1973, 13 I.L.M. 270, available at http://www.european-patent-
office.org/legal/epc/e/ma1.html; Directive 98/44/EC of the European Parliament and of the 
Council of 6 July 1998 on the Legal Protection of Biotechnological Inventions,1998 O.J.  
 (L 213) 13, available at http://eur-
lex.europa.eu/LexUriServ/site/en/oj/1998/l_213/l_21319980730en00130021.pdf. 
 90.  Agreement on Trade Related Aspects of Intellectual Property Rights, art. 31, available at 
http://www.wto.org/english/tratop_e/trips_e/t_agm3_e.htm#7.  Article 31 allows 
compulsory licensing where a government has attempted to negotiate with a patent holder 
on reasonable commercial terms for a reasonable period of time, the use of the patented 
technology must be to predominately supply the domestic market, and pays the patent 
holder adequate remuneration.  However, when faced with a national emergency, other 
extreme urgency, or for public non-commercial use, this negotiation requirement may be 
waived.  Id.  See generally World Trade Organization Ministerial Conference, Declaration 
on the TRIPS Agreement and Public Health, para 5, available at 
http://uww.globaltreatmentaccess.org/content/press_releases/01/111401_WTO_TRIPS_DE
CL.html; Anthony P. Valach, Jr., TRIPS: Protecting the Rights of Patent Holders and 
Addressing Public Health Issues in Developing Countries, 4 CHI.-KENT J. INTELL. PROP 
156, 156 (2005); Daniel J. Gervais, Intellectual Property, Trade and Development: The 
State of Play, 74 FORDHAM L. REV. 505, 508 (2005); Bradley Condon & Tapen Sinha, 
Global Diseases, Global Patents and Differential Treatment in WTO law: Criteria for 
Suspending Patent Obligations in Developing Countries, 26 NW. J. INT’L L. & BUS. 1 
(2005).  Although there is no general compulsory licensing provision in the US Patent Act, 
28 U.S.C. § 1498 allows the US government to exercise its eminent domain authority by 
granting compulsory licenses covering patented inventions.  Grace K. Avedissian, Global 
Implications of a Potential U.S. Policy Shift Toward Compulsory Licencing of Medical 
Inventions in a New Era of “Super-Terrorism”, 18 AM. U. INT’L L. REV. 237, 258 (2002). 
Under section 1498, when an invention protected by a US patent is used or manufactured by 
PP 57- MALINOWSKI (AA) 12/8/2006  2:50 PM 
 Ethics in a Global Biopharmaceutical Environment 73 
 
 
 
73
time, these provisions will become a vehicle to introduce an international human 
subjects protection standard directly through TRIPS/GATT.  Presently, the 
influence of neoliberal economic theory and commercial interests and the fledging 
status of extensive GATT/TRIPS implementation suggest otherwise.91 
A fourth option is to realize a compulsory international baseline standard for 
human subjects research as a common denominator essential to move global 
biopharmaceutical R&D forward through a freedom to contract, technology 
transfer model where incentives are introduced for adherence to international 
norms for human subject protections.  This positive incentive approach has proven 
extremely effective in US regulation of biopharmaceutical R&D from encouraging 
pediatric testing92 to the development of “orphan drugs” for small disease 
populations.93  One can at least imagine foreign countries following the example 
set by US universities which have harnessed their research resources to gain access 
to indigenous populations and their medical histories, the biodiversity in which 
they live, and their knowledge of the same94 through contracts with researchers and 
 
or for the US without obtaining a license from the patent holder, the patent holder’s sole 
remedy is to bring an action against the US for the recovery of reasonable compensation.  
28 U.S.C. § 1498. 
 91.  See generally Nuruzzaman, supra note 86. 
 92.  See Best Pharmaceuticals for Children Act, Pub. L. No. 107-109, 115 Stat. 1408, available 
at http://frwebgate.access.gpo.gov/cgi-
bin/getdoc.cgi?dbname=107_cong_bills&docid=f:s1789enr.txt.pdf. In its 2001 report to 
Congress on the program, the FDA declared “the industry’s response has been vigorous and 
the pubic health benefits have been extensive.”  U.S. FDA, Dep’t of Health & Hum. Servs., 
The Pediatric Exclusivity Provision: Jan. 2001 Report to Congress at 8 (2001), available at 
http://www.fda.gov/cder/pediatric /reportcong01.pdf.  See generally Michael S. Labson, 
Pediatric Priorities: Legislative and Regulatory Initiatives to Expand Research on the Use of 
Medicines in Pediatric Patients, 6 J. Health Care L. & Pol’y 34, 35 (2002); I.Glenn Cohen, 
Therapeutic Orphans, Pediatric Victims?  The Best Pharmaceuticals for Children Act and 
Existing Pediatric Human Subject Protection, 58 FOOD & DRUG L.J. 661 (2003); Lainie 
Friedman Ross & M. Justin Coffey, Women and Children First: Applicable to Lifeboats?  
Applicable to Human Experimentation?, 6 J. HEALTH CARE L. & POL’Y 14, 15 (2002); 
Lauren Hammer Breslow, Note, The Best Pharmaceuticals for Children Act of 2002: The 
Rise of the Voluntary Incentive Structure and Congressional Refusal to Require Pediatric 
Testing, 40 HARV. J. ON LEGIS. 133, 136 (2003). 
 93.  Orphan Drug Act, Pub. L. No. 94-414 § 526(a)(2), 96 Stat. 2049 (1982), codified as 
amended at 21 U.S.C. §360bb(2000), available at  http://frwebgate1.access.gpo.gov/cgi-
bin/waisgate.cgi?WAISdocID=549585412272+0+0+0&WAISaction=retrieve.  For 
discussion of the Orphan Drug Act and interesting discussion of use of rewards-based 
biopharmaceutical R&D law-policy, see generally Mark D. Shtilerman, Pharmaceutical 
Inventions: A Proposal for Risk-Sensitive Rewards, 46 IDEA 337 (2006). 
 94.  A prime, timely example is the kambo, a poisonous tree frog.  Paulo Prada, Poisonous Tree 
Frog Could Bring Wealth to Tribe in Brazilian Amazon, N.Y. TIMES, May 30, 2006, at C1, 
C6.  The government of Brazil is supporting the plan of an indigenous tribe to 
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research sponsors that encompass the desired human subjects protections. 95  Such 
an effort could be research sponsor-driven, academic research-driven, or some 
combination of the two.  As articulated forcefully by Lita Nelson, Director of the 
Technology Transfer Office at the Massachusetts Institute of Technology, 
academic research institutions are organized through entities such as the 
Association of University Technology Managers and the Licensing Executives 
Society, and they have the means through technology transfer terms to make health 
care resources much more available to developing economies—for example, by 
not granting exclusive licenses without building in protections for developing 
countries’ needs.96  The US is particularly well-suited to push such an initiative 
into motion given the concentration of global biopharmaceutical R&D originating 
from inside its borders, the non-exclusive licenses the U.S. Government holds on 
all intellectual property stemming from the extensive research it funds, and the 
academic research community’s dependence on Bayh-Dole and U.S. federal 
technology transfer policy.97  Universal human subjects protection standards and a 
program to implement them could be developed by the International Monetary 
Fund-World Bank and the World Trade Organization in conjunction with the 
United Nations Educational Scientific and Cultural Organization (UNESCO) and 
the World Health Organization, and a meaningful effort would likely draw support 
from the international science and medical organizations, including the World 
Medical Association, CIOMS, and the International AIDS Vaccine Initiative 
(IAVI).98  By drawing from the human subjects protection fabric recently woven 
through the International Haplotype Mapping Project,99 CIOMS guidelines,100 and 
other international biopharmaceutical R&D bioethics guidelines and experience, 
the flexible U.S. freedom to contract model for technology transfer could be 
 
commercialize secretions of the kambo for biotechnology R&D.  Id. 
 95.  We already have witnessed the technology transfer model being applied successfully in an 
analogous fashion through some biobanking experiences.  See generally Michael J. 
Malinowski, Technology  Transfer in BioBanking: Credits, Debits, and Population Health 
Futures, 33 L. MED. & ETHICS 54, 54-69 (2005). 
 96.  See generally Lita Nelsen, The Role of University Technology Transfer Operations in 
Assuring Access to Medicines and Vaccines in Developing Countries, 3 YALE J. HEALTH 
POL’Y  L. & ETHICS 301 (2003). 
 97.  See generally MICHAEL J. MALINOWSKI, BIOTECHNOLOGY: LAW, BUSINESS, AND 
REGULATION (1999 & supplements.). 
 98.  IAVI, established in 1996, funds R&D on HIV vaccines with the mission of linking 
industry and foreign countries.  See Yearby, supra note7, at 1148-1150.  For more 
information about IAVI, visit their Internet site at http://www.iavi.org/. 
 99.  For more information, visit the official site of the International Haplotype Mapping Project, 
at http://www.hapmap.org/. 
 100.  See supra note 46. 
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applied in a manner that emphasizes sensitivity towards local culture, norms, 
customs and needs.101 
Realistically, in the absence of a well-funded financial incentive based program 
through entities such as the World Bank102 and UNESCO,103 the implementation of 
compulsory, enforced international standards is a prerequisite to effectively utilize 
freedom to contract in this context.  It is simply unrealistic to expect countries with 
developing economies to self-police, especially when their populations suffer from 
unmet health care needs such as basic nutrition and diseases like malaria that are 
readily treatable in the developed world.  It also is unrealistic to expect commercial 
biopharmaceutical interests under immediate R&D pressures to act 
philanthropically for some projected long-term gain.104  Similarly, meaningful 
financial incentives are a prerequisite for realizing the recommendations made by 
the National Bioethics Advisory Commission (NBAC) active under former 
President Clinton.105  These recommendations emphasize that countries sponsoring 
international research on human subjects must increase the capacity of host 
countries to self regulate.106  However, host countries with developing economies 
 
 101.  But “[t]he IMF-World Bank policy package has arduously tried to create American style 
institutions in the developing countries defying their distinct social institutions, cultural 
values, historical contextualities and local specificities.”  Nuruzzaman, supra note 86, at 
119. 
 102.  It must be noted, however, that “[t]he World Bank failed to follow through on its pledges to 
spend up to $500 million to combat malaria, let its staff working on the disease shrink to 
zero, used false statistical data to claim success and wasted money on ineffective medicines, 
according to a group of public health experts writing in the British medical journal The 
Lancet.”  Celia W. Dugger, World Bank Failed in Fight Against Malaria, Health Experts 
Say, N.Y. TIMES, Apr. 25, 2006, at A5.  However, subsequently, the World Bank appointed 
a new president, Paul D. Wolfowitz, and introduced a new finance monitoring system.  Id. 
 103.  Cf. JEFFREY D. SACHS, THE END OF POVERTY: ECONOMIC POSSIBILITIES FOR OUR TIME 
(2005) (appealing to nations with developed economies to introduce financial incentives to 
harness industry resources and close the science gap between developed and developing 
economies); Daphne Eviatar, Spend $150 Billion Per Year To Cure World Poverty, N.Y. 
TIMES MAG., Nov. 7, 2004, 44-49. 
 104.  But see Daniel W. Fitzgerald & Angela Wasunna, Away From Exploitation and Towards 
Engagement: An Ethical Compass for Medical Researchers Working in Resource Poor 
Countries, 33 J.L. MED. & ETHICS 559 2005 (arguing that commercial entities are under an 
“ethical imperative to use their unique positions judiciously, and to the benefit of the host 
population” and proposing that a meaningful incentive is to build research capacity in host 
countries through the “creation of equitable working partnerships between wealth and poor 
countries”). 
 105.  See generally NBAC, Ethical and Policy Issues in International Research: Clinical Trials in 
Developing Countries (2001), available at  
 http://www.georgetown.edu/research/nrcbl/nbac/clinical/Vol1.pdf . 
 106.  Id. at I (Executive Summary). 
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that are eager to promote research within their borders and open access to resulting 
medicines are unlikely to meaningfully self regulate in the absence of imposed 
requirements or significant financial incentives. 107 
The most pragmatic approach may be to harness commercial forces to trigger a 
race to the top in human subjects’ protection through enforcement and 
enhancement of domestic US law given the scope of biomedical R&D undertaken 
by US based interests.108  Recent, well-documented human subjects’ controversies 
are telling.109  If the FDA and OHRP, drawing from the HapMap experience and 
Ethical, Legal and Social Implications Program (ELSI) fabric,110 were to generate 
workable standards for international population genetics and fully implement those 
standards with their enforcement powers, presumably major biopharmaceutical 
entities prosecuted would put pressure on the agencies to treat their competitors 
similarly.  Consistent enforcement among US-based biopharmaceutical interests 
could, in turn, inspire demand by them for an international baseline so that US 
interests are not disadvantaged.  In this manner, the same market forces that 
realized GATT/TRIPS could bring about an enforceable international standard for 
the protection of human subjects.  The FDA and OHRP should implement the 
standards they are responsible for enforcing in the international context and force 
this overdue event into motion. 
 
 107.  See generally Jennifer Kahn, A Nation of Guinea Pigs, WIRED MAG. Issue 14.03, Mar. 
2006, at 142 (addressing “How India became the global hot spot for drug trials”).  Many 
countries relax US standards, such as human clinical trial prerequisites and the 
administration of baseline treatments in conjunction with trials of potentially new 
medicines, and actively seek out study participation.  See generally Esther Chang, Fitting a 
Square Peg in a Round Hole?  Imposing Informed Consent and Post-Trial Obligations on 
United States Sponsored Clinical Trials in Developing Countries, 11 S. CAL. INTERDISC. 
L.J. 339 (2002).  The raw health care needs of many countries with developing economies 
have been used as justification for “manipulat[ing] unacceptable U.S. research risks into 
acceptable risks in foreign contexts, especially where large disparities in health resources 
exist between the United States and the host country.  Peter Lurie & Sidney M. Wolfe, 
Unethical Trials of Interventions to Reduce Perinatal Transmission of the Human 
Immunodeficiency Virus in Developing Countries, 337 NEW ENG. J. MED. 853, 855 (1997).  
The end result is that “researchers involved in these experiments have exploited the 
inadequacies of the health-care systems in these developing countries to conduct research 
they would never even consider in the US.  Roman, supra note 7, at 445. 
 108.  For detailed support, visit the web sites of the two major U.S. trade organizations — the 
Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology 
Industry Organization (BIO), at www.phrma.org and www.bio.org. 
 109.  Stephens et al., supra note 8. 
 110.  For information about the ELSI program, visit the site of the International Human Genome 
Research Institute at www.genome.gov, the National Institutes of Health site, www.nih.gov, 
and the Department of Energy site, www.doe.gov. 
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VI.  Conclusion 
Biopharmaceutical R&D is a global endeavor without a baseline rule of law to 
protect human subjects.  A solid compilation of compulsory, enforced international 
human subjects protections is needed.  This conclusion is illustrated graphically by 
the Harvard-Millennium controversy, the cluster of related controversies, and the 
voluminous ongoing appetite of researchers for access to human biological 
samples, related medical information, and human subjects in the shadow of the 
assembled map of the human genome.  This article has identified a number of 
options for establishing a workable baseline of protection of human subjects that 
would move research forward to make medical sense out of HGP in a responsible 
manner.  Let us jolt forward along the biopharmaceutical R&D path and without 
borders, but in a responsible, accountable manner. 
